🎙️ AbbVie Q1 2025 Earnings – Immunology Momentum, Raised Guidance, and Strategic Growth Moves📅 Earning Release: April 25, 2025📄 Sources: AbbVie Q1 2025 Earnings Release, Investor Charts, and Call TranscriptIn this episode, we break down AbbVie’s strong Q1 2025 results, pipeline updates, and future growth strategy beyond Humira.📈 Quarterly Highlights• Revenue: $13.3B (+8.4% YoY reported, +9.8% operational)• Adjusted EPS: $2.46 (+6.5% YoY), beating guidance midpoint• Raised full-year 2025 guidance: EPS now $12.09–$12.29, revenue forecast up $700M to ~$59.7B💊 Portfolio Performance• Immunology: Skyrizi (+70.5% YoY) and Rinvoq (+57.2% YoY) delivered combined $5.1B sales, offsetting Humira’s -50.6% decline• Neuroscience: Strong growth from Vraylar, Botox Therapeutic, and migraine portfolio (Ubrelvy, Qulipta)• Oncology: Solid contributions from Venclexta and Elahere despite Imbruvica erosion• Aesthetics: Revenue decline (-11.7% YoY) due to economic headwinds; long-term growth potential remains🚀 Pipeline and Strategic Investments• Obesity: New amylin analog program (ABBV-295) shows early promise• Oncology: Partnerships with Xilio and Nimble Therapeutics• Neuroscience: Positive Phase 3 data for Tavapadon in Parkinson's disease• Aesthetics: Submitted new fast-acting BoNT/E toxin for FDA approval🏭 Manufacturing and Tariff Readiness• Over $10B planned U.S. manufacturing investment over next decade• Strengthens resilience against potential pharmaceutical sector tariffs🔮 Management Outlook• Clear growth runway through at least 2029 with a high single-digit revenue CAGR• Continued investment focus across Immunology, Neuroscience, Oncology, Aesthetics, and now ObesityAbbVie is executing well on its post-Humira transformation — with strong portfolio momentum, expanding pipelines, and strategic initiatives driving future growth.#AbbVie #Earnings #Pharma #Biotech #Immunology #InvestingPodcast

Ver todos los episodios